Kenji Tamura
A5069272944- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Breast Cancer Treatment Studies
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- PI3K/AKT/mTOR signaling in cancer
- Iron and Steelmaking Processes
- Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Sarcoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- BRCA gene mutations in cancer
- Cancer Cells and Metastasis
- Endometrial and Cervical Cancer Treatments
- Cancer therapeutics and mechanisms
- Radiopharmaceutical Chemistry and Applications
- Chronic Lymphocytic Leukemia Research
- Protein Degradation and Inhibitors
- Metallurgical Processes and Thermodynamics
Shimane University Hospital
2020-2025
National Cancer Center Hospital East
2015-2024
Shimane University
2020-2024
National Institute for Materials Science
2024
Chuo Gakuin University
2008-2023
National Cancer Center
2012-2023
Tokyo National Hospital
2012-2023
Jikei University School of Medicine
2019-2023
Hitachi (Japan)
1997-2021
Johnson Controls (United States)
2021
Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and cytotoxic topoisomerase I inhibitor. In phase 1 dose-finding study, majority the patients with advanced HER2-positive breast cancer had response to trastuzumab (median duration, 20.7 months). The efficacy in metastatic previously treated emtansine requires confirmation.In this two-part, open-label, single-group,...
Breast cancer patients often develop metastatic disease years after resection of the primary tumor. The are asymptomatic because disseminated cells appear to become dormant and undetectable. Because proliferation these is slowed, unresponsive traditional chemotherapies that exploit rapid cell cycling most cells. We generated a bone marrow-metastatic human breast line (BM2) by tracking isolating fluorescent-labeled MDA-MB-231 marrow in mice. Coculturing BM2 with mesenchymal stem (BM-MSCs)...
Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with topoisomerase I inhibitor payload. A dose escalation and expansion phase study evaluated the safety activity of T-DXd in patients advanced HER2-expressing/mutated solid tumors. Here, results for at recommended doses (RDE) HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ hybridization-) breast cancer (ClinicalTrials.gov identifier:...
Brain metastasis is an important cause of mortality in breast cancer patients. A key event during brain the migration cells through blood-brain barrier (BBB). However, molecular mechanism behind passage this natural remains unclear. Here we show that cancer-derived extracellular vesicles (EVs), mediators cell-cell communication via delivery proteins and microRNAs (miRNAs), trigger breakdown BBB. Importantly, miR-181c promotes destruction BBB abnormal localization actin downregulation its...
BackgroundStandard first-line treatment of metastatic triple-negative breast cancer (mTNBC) is chemotherapy. However, outcomes are poor, and new options needed. In cohort B the phase II KEYNOTE-086 study, we evaluated pembrolizumab as therapy for patients with PD-L1-positive mTNBC.Patients methodsEligible had centrally confirmed mTNBC, no prior systemic anticancer disease, measurable disease at baseline per RECIST v1.1 by central review, radiographic evidence nervous system metastases, a...
Interstitial lung disease (ILD) is a serious adverse effect of gefitinib, but its prevalence and risk factors remain largely unknown. We examined the for gefitinib-induced ILD associated with practical use drug in Japanese non-small-cell cancer (NSCLC).Clinical information was retrospectively assembled NSCLC patients who started gefitinib treatment at affiliated institutions West Japan Thoracic Oncology Group between August 31 December 31, 2002. Medical records developed pulmonary...
MicroRNA (miRNA), which are stably present in serum, have been reported to be potentially useful for detecting cancer. In the study, we examined expression profiles of serum miRNA several large cohorts identify novel that can used detect early stage breast We comprehensively evaluated using highly sensitive microarray analysis. A total 1280 samples cancer patients stored National Cancer Center Biobank were used. addition, 2836 obtained from non‐cancer controls, 451 with other types cancers,...
Next-generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide management by providing information about actionable gene aberrations that have diagnostic and therapeutic significance. Here, we undertook a hospital-based prospective study (TOP-GEAR project, 2nd stage) to investigate the feasibility utility NGS-based analysis 114 cancer-associated genes (the NCC Oncopanel test). We examined 230 cases (comprising more than 30 types) advanced solid tumors, all which were...
Adjuvant abemaciclib combined with endocrine therapy (ET) previously demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free (DRFS) hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer at the second interim analysis, however follow-up was limited. Here, we present results of prespecified primary outcome analysis an additional analysis.This global, phase III,...
HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers. We assessed the safety/tolerability activity of novel antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in 60 patients with pretreated, HER2-expressing (IHC ≥ 1+), non-breast/non-gastric or HER2-mutant solid tumors from a phase I trial (NCT02564900). Most common (>50%) treatment-emergent adverse events (TEAE) were nausea, decreased appetite, vomiting. Two drug-related TEAEs associated fatal outcomes....
The purpose of this study was to determine the safety, distribution, internal dosimetry, and initial human epidermal growth factor receptor 2 (HER2)–positive tumor images <sup>64</sup>Cu-DOTA-trastuzumab in humans. <b>Methods</b>: PET performed on 6 patients with primary or metastatic HER2-positive breast cancer at 1, 24, 48 h after injection approximately 130 MBq probe <sup>64</sup>Cu-DOTA-trastuzumab. Radioactivity data were collected from blood, urine, normal-tissue samples these...
Treatment options for advanced thyroid cancer refractory to standard therapies are limited. The safety and efficacy of pembrolizumab were evaluated in patients with differentiated expressing programmed death ligand 1 (PD-L1). Patients enrolled the nonrandomized, phase Ib KEYNOTE-028 trial conducted evaluate antitumor activity anti–programmed (PD-1) antibody solid tumors. Key eligibility criteria papillary or follicular cancer, failure therapy, PD-L1 expression tumor stroma cells (assessed by...
Primary analysis of the multicenter, open-label, single-arm, phase II DESTINY-Breast01 trial (median follow-up 11.1 months) demonstrated durable antitumor activity with trastuzumab deruxtecan (T-DXd) in patients human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated emtansine (T-DM1). We report updated cumulative survival outcomes a median 26.5 months (data cut-off 26 March 2021).
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTOne-pot synthesis of trifluoroacetimidoyl halidesKenji Tamura, Hiromichi Mizukami, Kazuhiro Maeda, Hisayuki Watanabe, and Kenji UneyamaCite this: J. Org. Chem. 1993, 58, 1, 32–35Publication Date (Print):January 1993Publication History Published online1 May 2002Published inissue 1 January 1993https://doi.org/10.1021/jo00053a011RIGHTS & PERMISSIONSArticle Views4190Altmetric-Citations246LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant...
The purpose of this study was to evaluate the efficacy gefitinib and feasibility screening for epidermal growth factor receptor (EGFR) mutations among select patients with advanced non-small cell lung cancer (NSCLC). Stage IIIB/IV NSCLC, chemotherapy-naive or recurrences after up two prior chemotherapy regimens were eligible. Direct sequencing using DNA from tumour specimens performed by a central laboratory detect EGFR mutations. Patients harbouring received gefitinib. primary objective...